32 results about "Synthetic cannabinoids" patented technology

An orally dissolvable or chewable tableted powder formulation is presented. The formulation includes one or more carrier systems including one or more liquid or solid self-emulsifying systems loaded with cannabinoids in an amount of at least 10% by weight of the tableted powder formulation. The one or more self-emulsifying systems includes: at least one or more surfactants, one or more lipids and one or more isolated or synthetic cannabinoids when self-emulsifying system is a liquid self-emulsifying system, and at least one or more surfactants, one or more waxes and one or more isolated or synthetic cannabinoids when self-emulsifying system is a solid self-emulsifying system. The formulation further includes one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation and one or more flavors. The one or more surfactants includes one or more surfactants having a chemical structure that includes a polyethylene glycol moiety.

A method is provided for the synthesis of (-)-trans-Δ9-tetrahydrocannabivarin (Δ9-THCV) and analogs thereof such that in the reaction product, the molar ratio of the Δ9 isomer to incidentally formed Δ8 isomers is greater than 4:1. Synthesis is carried out by combining a selected cannabinoid reactant, e.g., cannabidivarin (CBDV) or an analog thereof, with an acid in a solvent for the cannabinoid reactant, wherein the acid comprises (i) a Lewis acid having an acid softness index value in the range of -10 ΔG0 f, M n+ to ‑150 ΔG0 f, M n+, (ii) a Brønsted acid having a pKa in the range of -4.0 to +4.0, or (iii) a combination of (i) and (ii), under reaction conditions comprising a reaction temperature in the range of ‑0 °C to 25 °C and a reaction time in the range of 1 hour to 24 hours. The reaction is thereafter quenched with base and the solvent removed, wherein the crude reaction product so provided may be purified, e.g., chromatographically purified. Also provided is a method for synthesizing Δ9-THCV that further includes synthesis of the cannabinoid reactant. The invention additionally provides novel cannabinoid compositions that may be synthesized using the aforementioned methodology.

An orally dissolvable or chewable tableted powder formulation is presented. The formulation includes one or more carrier systems including one or more liquid or solid self-emulsifying systems loaded with cannabinoids in an amount of at least 10% by weight of the tableted powder formulation. The one or more self-emulsifying systems includes: at least one or more surfactants, one or more lipids and one or more isolated or synthetic cannabinoids when self-emulsifying system is a liquid self-emulsifying system, and at least one or more surfactants, one or more waxes and one or more isolated or synthetic cannabinoids when self-emulsifying system is a solid self-emulsifying system. The formulation further includes one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation and one or more flavors. The one or more surfactants includes one or more surfactants having a chemical structure that includes a polyethylene glycol moiety.

Disclosed herein are novel CBGA and CBGVA synthases and methods for improving their overall activity for synthesizing CBGA and CBGVA from their respective precursors, olivetolic acid (OA) or divaleric acid (DVA), and GPP. Fusion proteins for enhancing the synthesis of CBGA and CBGVA are also disclosed. The methods described herein also increase the titer and purity of CBGA and CBGVA produced by cells by: 1) reducing the formation of the by-products FCBGA and FCBGVA, which are synthesized from the prenylation of OA and DVA, respectively, with FPP; 2) increasing the intracellular availability of OA and DVA; and 3) increasing the rate of CBGA and CBGVA formation while reducing the accumulation of intermediates.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

The invention discloses a synthetic cannabinoid nucleic acid aptamer and application thereof. The synthetic cannabinoid nucleic acid aptamer is shown as any one of nucleotide sequences SEQ ID NO.1-8. The invention further discloses a synthetic cannabinoid nucleic acid aptamer. According to the invention, a plurality of synthetic cannabinoid structures are taken as positive screening targets, a plurality of non-synthetic cannabinoid structures are taken as negative screening targets, and a plurality of nucleic acid aptamers with high affinity to the plurality of synthetic cannabinoid structures are screened based on a ligands index enrichment system evolution technology; the functional motif combined with the synthesized cannabinoid indazole-3-formamide framework structure is found for the first time. Through verification, the KD value of the aptamer and the inspected synthetic cannabinoid is 0.1-1.3 [mu] M, the detection linear range of ADB-PHETINACA in 50% artificial saliva by a fluorescent dye replacement detection method based on the aptamer is 20-400 ng / mL, the detection limit is 2.1 ng / mL, the sensitivity is high, the detection is rapid, the operation is simple and convenient, and the fluorescent dye replacement detection method can be used for rapid drug screening.

The invention provides a preparation method of an indazole synthetic cannabinoid deuterated internal standard substance, and relates to the technical field of cannabinoid deuterated internal standard substances, and the preparation method comprises the following steps: 1, reacting aniline-D5 with chloral hydrate and hydroxylamine hydrochloride in a sodium sulfate aqueous solution to generate a compound 1; step 2, performing acid action on the compound 1 to generate a compound 2; 3, carrying out ring opening, diazotization, reduction and cyclization on the compound 2 to form a compound 3; 4, reacting the compound 3 with halogenated alkane under an alkaline condition to generate a compound 4; 5, the compound 4 and an amine compound are subjected to an amide condensation reaction, and the indazole synthetic cannabinoid deuterated internal standard substance is obtained. The raw materials are cheap and easy to obtain, and the preparation method is simple, so that the purpose of green and safe preparation of the indazole synthetic cannabinoid deuterated internal standard substance is achieved, and powerful support is provided for judicial expertise and drug banning work.

Cannabinoid analogs may exhibit anti-inflammatory properties such as by inhibition of cannabinoid type 2 (CB2) receptors. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat various diseases and conditions in mammals, including pain, anxiety, a sleep disorder, addiction, epilepsy, depression, post-traumatic stress disorder or Alzheimer's disease. In some examples, the pharmaceutical compositions may be administered for treating a cognitive disorder or for improving cognition.

A capsule for peroral delivery of cannabinoids includes a cannabinoid formulation contained in a hard shell or soft shell of the capsule. The formulates include: one or more self-emulsifying drug delivery systems (SEDDS) including one or more surfactants having a chemical structure that includes a polyethylene glycol (PEG) moiety in an amount of at least 20% by weight of the one or more SEDDS; and one or more cannabinoids including one or more isolated or synthetic cannabinoids in an amount of at least 10% by weight of the formulation.

Cannabinoid analogs disclosed herein may exhibit antibacterial and anti-inflammatory properties. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) infections, as well as various disorders associated with chronic inflammation, such as arthritis. In some aspects, a pharmaceutical composition may be administered to an individual who has been exposed or is at risk of exposure to Bacillus anthracis or Bacillus anthracis spores.

The present invention relates to a capsule for peroral delivery of cannabinoids comprising a cannabinoid formulation contained in a hard shell or soft shell of the capsule. The formulates comprises: one or more self-emulsifying drug delivery systems (SEDDS) comprising one or more surfactants having a chemical structure that includes a polyethylene glycol (PEG) moiety in an amount of at least 20% by weight of the one or more SEDDS; and one or more cannabinoids comprising one or more isolated or synthetic cannabinoids in an amount of at least 10% by weight of the formulation.

The invention relates to a post-modified covalent organic framework sensing reagent for detecting synthetic cannabinoid EG-2201, a lateral flow chromatography device and a detection method. According to the method, naphthalene-2, 6-diamine, anthracene-2, 6-diamine or 2, 7-pyrene diamine and 5 '-(4-formyl-3-hydroxyphenyl)-3, 3 ''-dihydroxy-[1, 1': 3 ', 1''-terphenyl]-4, 4 ''-dicarboxaldehyde are respectively subjected to a solvothermal method to prepare a naphthyl covalent organic framework material, an anthryl covalent organic framework material or a pyrene covalent organic framework material, and the naphthyl covalent organic framework material, the anthryl covalent organic framework material or the pyrene covalent organic framework material is used for preparing the naphthyl covalent organic framework material, the anthryl covalent organic framework material or the pyrene covalent organic framework material. Then carrying out post-modification by using a naphthalimide small-molecule probe to obtain a post-modified covalent organic framework sensing reagent; when the synthesized cannabinoid EG-2201 is detected under 365 nm illumination, ratio fluorescence phenomena of changing from yellow to green, changing from blue to green and changing from green to yellow are shown, the detection sensitivity of the reagent is high, the detection limit is 137.1 nM, and the response time is immediate. The method has high selectivity, can realize efficient and convenient real-time detection of synthetic cannabinoid EG-2201, and can be used for on-site rapid screening detection.

The present invention relates to a dosage form for delivery of cannabinoids comprising a formulation, the formulation comprising: one or more self-emulsifying drug delivery systems (SEDDS) comprising one or more surfactants having a chemical structure that includes a polyethylene glycol (PEG) moiety in an amount of at least 30% by weight of the one or more SEDDS; and one or more cannabinoids comprising one or more isolated or synthetic cannabinoids in an amount of at least 10% by weight of the formulation.

The invention relates to a fluorescence detection reagent for on-site rapid classification and identification of synthetic cannabinoid. According to the detection reagent, based on a steric hindrance engineering thermodynamic gating strategy, a fluorescent probe molecule tert-butyl (4-(2-(4-hydroxybutyl)-1, 3-dioxo-2, 3-dihydro-1H-benzo [de] isoquinoline-6-yl) phenyl) carbamate containing a specific steric hindrance group (Boc group) is designed and synthesized. And the probe forms a fluorescence quenching aggregate in a thermodynamic metastable state in a system. The aggregate constructs a specific energy threshold value, and only when the aggregate encounters synthetic cannabinoid of a high affinity category (simultaneously having a keto / ester head and a hydrophobic tail chain), dissociation of the aggregate is synergistically triggered through multiple non-covalent interaction, and a remarkable fluorescent lightening signal is generated. The response time is less than 1 s, the detection limit can reach the microgram level, and the method has the characteristics of simplicity and convenience in operation, strong anti-interference performance (no false positive), convenience in visual observation and the like. The problem that a traditional single-molecule probe is difficult to classify and identify synthetic cannabinoid in a complex matrix is solved, and powerful technical support is provided for on-site investigation of drugs.

Disclosed are fluorescent tags comprising a cannabinoid fluorophore and compositions comprising the fluorescent tags.

The application discloses a kind of based on CB2R functionalized gold electrode synthetic cannabinoid detection method.The application constructs a kind of high specificity, high stability biological sensitive interface by sequentially modifying SH-PEG-NTA, CuSO4 and CB2R on the surface of gold electrode.The functionalized electrode can utilize the specific binding of CB2R and synthetic cannabinoid in solution, realize the sensitive detection of synthetic cannabinoid by detecting the change of physical or electrochemical property of electrode interface before and after binding.The method has the advantages of good selectivity, strong anti-interference ability, etc.The prepared functionalized electrode can be used as a sensitive element, and provides an innovative technical solution for developing portable synthetic cannabinoid detection equipment.

A method for producing a cannabinoid by contacting cannabigerolic acid with a cannabinoid synthase orthologue. The cannabinoid synthase orthologue is from an organism other than Cannabis sativa. Also disclosed is a recombinant cell of Saccharomyces cerevisiae or Pichia pastoris that includes in its genome a nucleic acid encoding the above cannabinoid synthase orthologue. The cannabinoid synthase orthologue is expressed in the recombinant cell in an active form.

This invention provides enzymes and methods for synthesizing cannabinoids specifically and in high yield. [Solution] A method is provided for producing one or more cannabinoids, comprising the step of contacting cannabigerol acid with a cannabinoid synthase ortholog. The cannabinoid synthase ortholog is derived from an organism other than hemp (Cannabis sativa). Also disclosed are recombinant cells of Saccharomyces cerevisiae or Pichia pastoris, which contain nucleic acids encoding the cannabinoid synthase ortholog in their genome. The cannabinoid synthase ortholog is expressed in its active form in the recombinant cells.

The application provides a preparation method and application of a spatial type surface enhanced Raman probe, and belongs to the technical field of preparation of the surface enhanced Raman probe. The hot spot of the probe takes a dielectric material-metal combination as a core, takes cetyltrimethylammonium bromide (CTAB) as a hard template on the surface of the core, synthesizes a mesoporous silica layer through one-pot wet chemical method, realizes a double-layer spatial type structure by chemical plating of metal particles on the surface again, the number of layers of the structure can be adjusted, the preparation of a more efficient 'hot spot' is realized, and the prepared enhanced Raman probe can be used for trace detection of cannabinoids.

The non-small cell lung cancer adenocarcinoma via the pathway mediated with the cannabinoid receptor is targeted for the first time with the synthetic cannabinoid agonist arachidonoyl cyclopropylamide (ACPA). An ACPA-PCL nanoparticle release system based on nanoengineering provides long term-controlled release and stability of the CB1 receptor agonist ACPA following the determination of the efficient dose and the antiproliferative effect of ACPA on the non-small cell lung cancer lines expressing the cannabinoid (CB) receptors in vitro medium at different doses.

The present application belongs to the technical field of drug detection, and provides a broad-spectrum aptamer for recognizing 22 synthetic cannabinoids and an application thereof to solve the problem of detecting synthetic cannabinoids. The broad-spectrum aptamer is a single-stranded DNA molecule sequence as shown in SEQ ID NO: 5. The present application takes two existing nucleic acid aptamers as original aptamers, preliminarily predicts the binding mechanism of the nucleic acid aptamers and synthetic cannabinoids through molecular docking, further analyzes the interaction between the nucleic acid aptamers and the target in the base level through molecular dynamics simulation, optimizes the nucleic acid aptamers by truncation, and screens out aptamers capable of highly specifically recognizing 22 synthetic cannabinoids, which are few in base number, good in stability, easy to synthesize, and easy to modify or label functional groups. The aptamers can distinguish synthetic cannabinoids from other common drugs, verify the reliability thereof, can stably bind to 22 synthetic cannabinoids, and exhibit broad-spectrum recognition ability for synthetic cannabinoids.

To provide enzymes and methods for synthesizing cannabinoids with specificity and a high yield.SOLUTION: Provided herein is a method for generating one or more cannabinoids, comprising a step of contacting cannabigerolic acid to a cannabinoid synthase ortholog. The cannabinoid synthase ortholog derives from organisms other than Cannabis sativa. Also disclosed is a recombinant cell of Saccharomyces cerevisiae or Pichia pastoris comprising a nucleic acid encoding the cannabinoid synthase ortholog in the genome. The cannabinoid synthase ortholog is expressed in the recombinant cell in an active form.SELECTED DRAWING: Figure 1

The invention provides a preparation method and application of a spatial surface-enhanced Raman probe, and belongs to the technical field of preparation of surface-enhanced Raman probes. A hot spot of the probe takes a dielectric material-metal combination as an inner core, cetyltrimethylammonium bromide (CTAB) is taken as a hard template on the surface, a mesoporous silica layer is synthesized by a one-pot wet chemical method, metal particles are chemically plated on the surface again to realize a double-layer spatial structure, the number of layers of the structure can be adjusted, and the preparation of the hot spot with higher efficiency is realized. The enhanced Raman probe prepared by the invention can be used for trace detection of synthetic cannabinoid.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

This invention belongs to the field of environmental analytical chemistry, specifically a wastewater analysis method for the simultaneous detection of multiple synthetic cannabinoids and their metabolites. This invention employs a micro-volume direct injection method combined with ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS / MS) for qualitative and quantitative analysis of 72 synthetic cannabinoids and their metabolites in wastewater samples. This invention eliminates the need for complex pretreatment processes such as solid-phase extraction, is simple to operate, has a short analysis time, high sensitivity, and wide coverage, making it suitable for high-throughput monitoring of synthetic cannabinoids in wastewater.

This invention relates to a group of synthetic cannabinoid compounds having structural formula I as defined herein. The invention also relates to compositions comprising these compounds, methods for preparing these compounds, intermediates that can be used to prepare these compounds, and the use of these compounds as medicines, particularly for treating conditions associated with seizures such as epilepsy.

This invention discloses a synthetic cannabinoid monoclonal antibody and its application in the preparation of a detection kit for synthetic cannabinoids and structural analogues, belonging to the field of drug detection technology. The amino acid sequence of the heavy chain variable region of the synthetic cannabinoid monoclonal antibody is shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2. The monoclonal antibody of this invention can effectively recognize 29 synthetic cannabinoids and structural analogues. This invention utilizes this monoclonal antibody to prepare a kit for detecting synthetic cannabinoids, which can efficiently detect synthetic cannabinoids or their metabolites in human urine. It is used for on-site screening of drug use and has significant advantages such as rapid detection, high sensitivity, broad spectrum, and suitability for rapid on-site screening.

Cannabinoid analogs may exhibit anti-inflammatory properties such as by inhibition of cannabinoid type 2 (CB2) receptors. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat neurological disorders and various other diseases and conditions in mammals, including pain, anxiety, sleep disorders, obesity and eating disorders, addiction, epilepsy, depression, post-traumatic stress disorder, Alzheimer's disease, bacterial infections and viral infections.